Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
Cellectar Biosciences, Inc. (NASDAQ: CLRB) will announce its first-quarter financial results on May 14, 2024. The company focuses on developing cancer treatments and will host a conference call to discuss the results and provide an overview at 8:30 am Eastern Time.
- None.
- None.
FLORHAM PARK, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the three months ended March 31, 2024, on Tuesday, May 14, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows:
| Conference Call & Webcast Details: | ||
| Date: | Tuesday, May 14 | |
| Time: | 8:30 am Eastern Time | |
| Toll Free: | 1-800-717-1738 | |
| Webcast: | Click HERE | |
| Call me™ | Click HERE | |
Participants may use the dial-in numbers above for an operator OR click the Call meTM link for instant telephone access to the event. The Call meTM link will be made active 15 minutes prior to the scheduled start time.
A replay of the call will be available on Events section of the company’s investor relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Contacts
MEDIA:
Claire LaCagnina
Bliss Bio Health
315-765-1462
clacagnina@blissbiohealth.com
INVESTORS:
Chad Kolean
Chief Financial Officer
investors@cellectar.com
FAQ
When will Cellectar Biosciences announce its first-quarter financial results?
What is the focus of Cellectar Biosciences business?
What is the stock symbol for Cellectar Biosciences?
When will the conference call with investors take place?
How can participants access the conference call?
Will there be a replay of the conference call available?
